Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46579 | 0.67 | ALDH1A1 (0.53) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL1102002 | 0.62 | ALDH1A1 (0.70) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL28704993 | 0.62 | CA9 (0.50) | ALDH1A1MAPTNPC1KMT2ALMNA | |
| SCHEMBL11324184 | 0.62 | MEN1 (0.74) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL11329898 | 0.62 | CA9 (0.77) | ALDH1A1MAPTLMNAAURKAMAPK1 | |
| SCHEMBL11329893 | 0.62 | CA9 (0.77) | ALDH1A1MAPTLMNAAURKAMAPK1 | |
| SCHEMBL12177166 | 0.61 | AURKA (0.70) | PSMB8ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL17309290 | 0.61 | MEN1 (0.79) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL12013235 | 0.61 | MEN1 (0.79) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL11331666 | 0.61 | MEN1 (0.79) | ALDH1A1MAPTKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148541-B1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-2952188-A1 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | Universität Bern (CH) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015181336-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | SLC18A2, AANAT, CNR2 | PSMB8 4562/4885ALDH1A1 395/4885MAPT 196/4885 |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | SLC18A2, AANAT, CNR2 | PSMB8 4562/4885ALDH1A1 395/4885MAPT 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.